Sartorius expands biopharma manufacturing in Slovenia

By The Science Advisory Board staff writers

Sartorius plans to expand production facilities for purification products for vaccines and therapies at its facility in Ajdovscina, Slovenia.

The manufacturing and lab space will more than double from 3,000 sq m to 6,200 sq m. In 2021, the company will invest more than 400 million euros ($487.9 million U.S.) in manufacturing capacities around the world to keep up with demand.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?